Fed. Circ. Limits Scope Of Biogen's MS Drug Patent Extension
A Delaware federal court rightly found that Banner Life Sciences didn't infringe a Biogen patent with its rival version of the company's blockbuster multiple sclerosis drug Tecfidera, since the patent's extended...To view the full article, register now.
Already a subscriber? Click here to view full article